君實生物(01877.HK)與Coherus簽署許可與商業化協議
君實生物(01877.HK)公布,與生物製藥公司Coherus Biosciences, Inc.簽署獨佔許可與商業化協議。據此,Coherus獲授獨佔許可以開發、製造、商業化、銷售及以其他方式利用被稱為JS001的單克隆抗體,以及任何後繼抗PD-1單特異性抗體及在美國及加拿大境內用於治療或預防人類疾病含有JS001的任何產品。
針對授予JS001的許可及兩個可選項目,公司最高可收到來自Coherus總額11.1億美元的首付款、可選項目執行費及里程碑款。其中,包括協議生效後的一次性不可退還首付款1.5億美元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.